Our Story » Opportunity » Team
Our Story
At Doron Therapeutics, we believe “Mobility is a Gift.” That’s why we strive to develop and deliver biotechnologies that help people get moving again.
History
Bioventus is a publicly traded company. A leading player in the field of OA, with a portfolio of 3 HA products.
MOTYS™ Development initiated in 2019 as a key pipeline program.
Bioventus has been the sole investor to date.
In April 2022, due to financial constraints, Bioventus announced its plan to divest the asset.
Key management involved in the program led Phase 2 study to completion.
Doron Therapeutics
spin-off was created in 2023 — Bioventus remains a minority shareholder.
Contact Us
Our team can help to answer any of your questions.
Get in touch to learn more about Doron Therapeutics.